Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

52.10USD
16 Jan 2018
Change (% chg)

$-4.50 (-7.95%)
Prev Close
$56.60
Open
$56.55
Day's High
$57.50
Day's Low
$51.35
Volume
367,039
Avg. Vol
258,011
52-wk High
$57.75
52-wk Low
$14.75

Select another date:

Tue, Jan 9 2018

BRIEF-GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease

* GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD) Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering

* GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Global Blood Therapeutics says DSMB safety review for phase 3 HOPE study completed

* Global Blood Therapeutics announces completion of safety review by independent data and safety monitoring board (DSMB) for phase 3 HOPE study in sickle cell disease Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics posts Q3 loss per share $0.66

* Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results

BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440

* Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440

BRIEF-Global Blood Therapeutics announces discontinuation of IPF program

* Global Blood Therapeutics announces discontinuation of Idiopathic Pulmonary Fibrosis (IPF) program​

BRIEF-Point72 Asset Management LP reports 5.2 pct passive stake in Global Blood Therapeutics

* Point72 Asset Management LP reports 5.2 percent passive stake in Global Blood Therapeutics Inc ‍​as of October 2 - SEC filing Source text: (http://bit.ly/2yH9e9Y) Further company coverage:

BRIEF-Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease

* Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease (scd) Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics Q2 loss per share $0.55

* Global Blood Therapeutics reports recent business progress and provides second quarter 2017 financial results

Select another date: